Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Abril 2019 - 5:30PM
Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage
biopharmaceutical company leveraging its proprietary knowledge of
MetAP2 systems biology to develop novel therapies for patients
affected by a range of metabolic diseases, today
announced that on April 2, 2019, the Company granted to Priya
Singhal, M.D., M.P.H., the Company’s Head of Research and
Development, an option to purchase 375,000 shares of the Company’s
common stock, with 25% of the option shares vesting on March 4,
2020 and the balance vesting in equal monthly installments over the
next three years, subject to her continued service to the Company
through each vesting date. The option is subject to acceleration
upon a change in control. The grant was made as a stand-alone
inducement award agreement outside of the 2014 Stock Option and
Incentive Plan as a material inducement to Dr. Singhal’s acceptance
of employment with the Company in accordance with NASDAQ Listing
Rule 5635(c)(4).
About Zafgen Zafgen (Nasdaq:ZFGN) is
a clinical-stage biopharmaceutical company leveraging its
proprietary MetAP2 biology platform to develop novel therapies for
patients affected by complex metabolic
diseases. Zafgen has pioneered the study of MetAP2
inhibitors in both common and rare metabolic disorders and is
currently advancing programs for type 2 diabetes, Prader-Willi
syndrome and liver diseases. Learn more at www.zafgen.com.
Media/Investor Relations Contacts: Zafgen, Inc.
Patricia Allen Chief Financial Officer 617-648-9792
Media Krystle Gibbs Ten Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
Investors John Woolford Westwicke, An ICR Company
john.woolford@westwicke.com 443-213-0506
Zafgen (NASDAQ:ZFGN)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Zafgen (NASDAQ:ZFGN)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Zafgen Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de